Healthcare Industry Insights

Friday, 20 September 2024

Veterinary Imaging Market Size, Share, Growth | Industry Report, 2030

The global Veterinary Imaging Market size is projected to reach USD 2.9 billion by 2030, registering a CAGR of 7.01% over the forecast period, according to a new report by Grand View Research, Inc. The market growth can be attributed to the rising penetration of diagnostic imaging technology in therapeutic applications in pets and livestock animals. Moreover, rising pet ownership and humanization, rising incidence of zoonotic disease in animals, increased focus on preventive healthcare, advancements in technology, and rising awareness and education.

The increasing trend of pet humanization and ownership across different countries has led to a rise in pet insurance enrollment rates across the globe. Radiography is one of the most common diagnostic tests covered by pet insurance. Thus, growing adoption of pet insurance and increasing awareness of the various diagnostic & treatment options available for pets are some of the factors driving the market growth. For instance, as per North American Pet Health Insurance Association (NAPHIA) data published in 2023, the overall number of pets insured by the end of 2023 in the U.S. was 5.36 million. This reflects an increase in several diagnostic imaging performed on pets in veterinary hospitals across the U.S.

In addition, an increase in product launches for small animal diagnostic imaging is expected to drive the segment growth. For instance, in June 2023, Sunset Vet introduced the first Veterinary Computed Tomography (CT) service in Indonesia, aiming to revolutionize small animal veterinary imaging. With advanced technology, including high-resolution imaging and rapid, noninvasive procedures, Sunset Vet offers precise diagnoses and tailored treatment plans. Similarly, in June 2023, iCRco, Inc. installed its CLARIS V Cone Beam Computed Tomography (CBCT) imaging device at the Santa Barbara Zoo, marking its 4th anniversary. This advanced technology facilitates precise 3D imaging of exotic animals, enhancing veterinary care through noninvasive and efficient diagnosis. The collaboration underscores the zoo's commitment to leveraging cutting-edge veterinary imaging solutions for the welfare of small animals.

Request a free sample copy or view report summary: Veterinary Imaging Market Report

Veterinary Imaging Market Report Highlights

In terms of product, the X-ray segment held the largest revenue share of 37.54% in 2023. X-ray is one of the most common diagnostic tests covered by pet insurance. Thus, rising pet insurance adoption and increased awareness of the various radiographic imaging solutions available for pets are contributing to segment growth.
In 2023, the small animals segment accounted for the largest share of the market by animal type and is expected to witness the fastest CAGR over the forecast period due to an increase in pet population, growing adoption of pet insurance, and increasing product launches.
Based on solution, the equipment segment dominated the global market with a share of 55.65% in 2023. On the other hand, the PACS segment is expected to witness the fastest CAGR over the forecast period.
Based on application, the Orthopedics and Traumatology segment dominated the global market with a share of 37.70% in 2023. On the other hand, the oncology segment is expected to witness the fastest CAGR over the forecast period.
Based on end use, the veterinary hospitals & clinics segment dominated the global market with a share of 64.86% in 2023 and is expected to witness the fastest CAGR over the forecast period.
The North America region dominated the global market with a share of 40.84% in 2023. North America has a highly developed veterinary healthcare infrastructure with numerous clinics, hospitals, and specialty centers equipped with advanced diagnostic and treatment capabilities. This advanced infrastructure enables veterinarians to diagnose and manage conditions like joint diseases (such as osteoarthritis) and ligament injuries in animals more effectively, leading to a higher demand for veterinary imaging.
Asia Pacific is expected to witness the fastest CAGR over the forecast period due to growing pet ownership rates, increasing awareness of veterinary imaging services, and growing strategic activities between key players to expand geographic footprints.

Veterinary Imaging Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 2.0 billion
Revenue forecast in 2030	USD 2.9 billion
Growth Rate	CAGR of 7.01% from 2024 to 2030
Actual data	2018 - 2022
Forecast period	2024 - 2030

Related Press Release@ Veterinary Imaging Industry Analysis

Veterinary Imaging Market Segmentation

Grand View Research has segmented the global veterinary imaging market based on product, solutions, animal type, application, end use, and region:

Veterinary Imaging Product Outlook (Revenue, USD Million; 2018 - 2030)

X-ray
Ultrasound
MRI
CT Imaging
Video Endoscopy

Veterinary Imaging Solutions Outlook (Revenue, USD Million; 2018 - 2030)

Equipment
Accessories/ Consumables
PACS

Veterinary Imaging Animal Type Outlook (Revenue, USD Million; 2018 - 2030)

Small Animals
Large Animals

Veterinary Imaging Application Outlook (Revenue, USD Million; 2018 - 2030)

Orthopedics And Traumatology
Oncology
Cardiology
Neurology
Respiratory
Dental Application
Other

Veterinary Imaging End-use Outlook (Revenue, USD Million; 2018 - 2030)

Veterinary Clinics & Hospitals
Other End-use

Veterinary Imaging Market Regional Outlook (Revenue, USD Million; 2018 - 2030)

North America

U.S.
Canada

Europe

Germany
U.K.
France
Italy
Spain
Netherlands
Sweden
Denmark
Norway
Poland
Rest of Europe

Asia Pacific

Japan
China
India
South Korea
Australia
Thailand
Rest of Asia Pacific

Latin America

Brazil
Mexico
Argentina
Rest of Latin America

Middle East & Africa

South Africa
Saudi Arabia
UAE
Rest of Middle East & Africa

Explore Horizon, the world's most expansive market research database

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Thursday, 19 September 2024

Plasma Protease C1-inhibitor Market To Reach $6.21 Billion By 2030

The global Plasma Protease C1-Inhibitor Market size is anticipated to reach USD 6.21 billion by 2030, expanding at a CAGR of 9.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. The global market for plasma protease C1-inhibitor is propelled by multiple pivotal factors such as the rising incidence of hereditary angioedema (HAE), a rare genetic disorder, increases the demand for effective therapies such as C1-inhibitor. Furthermore, advancements in biotechnology improve production efficiency, making these therapies more accessible.

Increased awareness and improved diagnosis of HAE and related conditions further contribute to substantial market growth. HAE affects approximately 1 in 50,000 individuals worldwide, underscoring the urgent need for therapies to alleviate symptoms and improve patient quality of life. Furthermore, advancements in biotechnology have enabled the development of recombinant products, which promise enhanced efficacy and accessibility for patients globally. These drivers are pivotal in shaping the landscape of the C1-INH industry, facilitating greater adoption and investment in novel treatment options.

Innovations in therapies are set to redefine treatment standards across various conditions. For instance, the introduction of long-acting formulations offers extended therapeutic effects, reducing treatment frequency and improving patient compliance. Additionally, ongoing research into new indications beyond HAE, such as antibody-mediated autoimmune diseases, showcases the versatility and potential of therapies in addressing unmet medical needs. These advancements underscore the dynamic nature of the industry, driven by continuous research and development efforts aimed at expanding therapeutic applications and optimizing patient outcomes.

Industry continues to expand; market players are increasingly focused on addressing key challenges and seizing opportunities for growth. Regulatory advancements and favorable reimbursement policies are anticipated to further propel market expansion, facilitating greater accessibility to C1-INH therapies for patients globally. Market players are leveraging these regulatory developments to streamline industry entry processes and ensure timely access to innovative treatments. Companies such as CSL Behring and Takeda Pharmaceutical are actively investing in expanding production capacities to meet escalating demand and ensure global supply chain resilience. Moreover, partnerships with research institutions and regulatory bodies are fostering innovation and accelerating the approval process for new C1-INH therapies. These proactive measures underscore a commitment to advancing treatment options and reinforcing market leadership, positioning stakeholders for sustained growth and success in the evolving healthcare landscape.

List of key players in the Plasma Protease C1-Inhibitor Market

CSL.
Takeda Pharmaceutical Company Limited
Pharming
KalVista Pharmaceuticals.
Sanquin.
BioCryst Pharmaceuticals, Inc.
CENTOGENE N.V.

Request a free sample copy or view report summary: Plasma Protease C1-inhibitor Market Report

Plasma Protease C1-inhibitor Market Report Highlights

Based on drug class, C1-inhibitors dominated the market and accounted for the largest share in 2023. Selective bradykinin B2 receptor antagonist anticipated to grow at the fastest growth rate over the forecast period owing to undergoing R&D initiatives being undertaken by major players
Based on dosage form, the lyophilized segment held a dominant share in 2023 due to their stability, longer shelf life, and ease of storage and transportation, making them preferred for plasma protease C1-inhibitor therapies, ensuring efficacy and convenience for patients and healthcare providers alike
Based on distribution channel, hospital pharmacies dominated the market in 2023 due to their widespread accessibility, regulatory compliance, and ability to handle specialized therapies like plasma protease C1-inhibitor effectively
North America dominated the market and accounted for the largest share in 2023 owing to high healthcare spending, advanced healthcare infrastructure, robust research, and significant adoption of Plasma Protease C1-inhibitor therapies for various rare diseases like hereditary angioedema.

Plasma Protease C1-inhibitor Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 3.54 billion
Revenue forecast in 2030	USD 6.21 billion
Growth Rate	CAGR of 9.79% from 2024 to 2030
Actual data	2018 - 2023
Forecast period	2024 - 2030

Related Press Release@ Plasma Protease C1-inhibitor Industry Analysis

Plasma Protease C1-inhibitor Market Segmentation

Grand View Research has segmented the plasma protease C1-inhibitor market based on drug class, dosage form, distribution channel and region:

Plasma Protease C1-inhibitor Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

C1-inhibitors

C1-esterase Inhibitor
Recombinant Inhibitor

Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

Plasma Protease C1-inhibitor Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)

Lyphophlised
Injectables

Plasma Protease C1-inhibitor Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Plasma Protease C1-inhibitor Region Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.
Canada
Mexico

Europe

UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway

Asia Pacific

Japan
China
India
Thailand
South Korea
Australia

Latin America

Brazil
Argentina

Middle East & Africa

South Africa
Saudi Arabia
UAE
Kuwait

Explore Horizon, the world's most expansive market research database

South Korea Botulinum Toxin Type A Market Size is Predicted to Witness 10.4% CAGR till 2030

The South Korea Botulinum Toxin Type A Market size is anticipated to reach USD 386.9 million by 2030 and expanding at a CAGR of 10.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising aesthetic consciousness among the South Korean population fuels the demand for the market. South Koreans place a high value on physical appearance, with a strong cultural emphasis on beauty and youthfulness. This societal trend has led to an increasing demand for non-invasive cosmetic procedures, including botulinum toxin treatments, to enhance and maintain one's appearance. For instance, the popularity of K-beauty standards and the influence of media and celebrities have heightened awareness and acceptance of aesthetic treatments. This growing focus on aesthetics is not limited to any specific age group, as both younger and older demographics are seeking treatments to address their cosmetic concerns, further driving the market for botulinum toxin products.

The growing consumer preference for health, safety, and authenticity has driven a strong focus on natural and organic products. According to the International Trade Administration article published in September 2023, despite a slight decrease in total local production and exports in 2022, South Korea remains one of the top 10 beauty markets globally. This trend presents new opportunities in the botulinum toxin type A market as consumers increasingly seek safe and natural cosmetic solutions. Additionally, the Ministry of Food & Drug Safety (MFDS) has introduced guidelines for natural and organic cosmetics, supporting the development and growth of this niche market within the botulinum toxin sector.

List of Key Players in the South Korea Botulinum Toxin Type A Market

Hugel
Medytox
Daewoong
Galderma
Ipsen
Huons Global
Pharma Research BIO
AbbVie

Request a free sample copy or view report summary: South Korea Botulinum Toxin Type A Market Report

South Korea Botulinum Toxin Type A Market Report Highlights

In terms of application, the upper face segment held the largest share of 51.85% in 2023 and is anticipated to grow at fastest growth rate over the forecast period owing to increasing demand for aesthetic treatments aimed at reducing wrinkles in areas such as the forehead, glabella, and crow's feet.
Based on gender, the female segment held the largest share of 82.02% as women in South Korea often experience early signs of aging and skin dullness, influenced by hormonal fluctuations such as declining estrogen levels.
Based on age, 31 to 59 Years segment held the largest share of over 44.35% in 2023. This age group is typically more concerned with signs of aging such as wrinkles and fine lines, making botulinum toxin type A injections a popular choice for rejuvenating facial appearance.
Based on end use, the specialty clinics & aesthetic centers segment held the largest share of over 42.99% in 2023. These facilities provide a range of cosmetic procedures under one roof, catering to diverse patient needs. Moreover, clinics employ skilled dermatologists and aesthetic practitioners who specialize in facial rejuvenation and cosmetic enhancements.

South Korea Botulinum Toxin Type A Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 214.0 million
Revenue forecast in 2030	USD 386.9 million
Growth rate	CAGR of 10.4% from 2024 to 2030
Historical data	2018 - 2023
Forecast period	2024 - 2030

Related Press Release@ South Korea Botulinum Toxin Type A Industry Analysis

South Korea Botulinum Toxin Type A Market Segmentation

Grand View Research has segmented the South Korea Botulinum Toxin Type A market based on application, gender, age, and end-use.

South Korea Botulinum Toxin Type A Application Category Outlook (Revenue, USD Million; 2018 - 2030)

Upper Face

Glabellar Wrinkles
Forehead Wrinkles
Crow’s Feet

Mid Face
Lower Face
Body

South Korea Botulinum Toxin Type A Gender Outlook (Revenue, USD Million; 2018 - 2030)

Female
Male

South Korea Botulinum Toxin Type A Age Outlook (Revenue, USD Million; 2018 - 2030)

Below 30 Years
31 to 59 Years
Over 60 Years

South Korea Botulinum Toxin Type A End-use Outlook (Revenue, USD Million; 2018 - 2030)

Hospitals
Specialty Clinics & Aesthetic Centers
Medspas

Explore Horizon, the world's most expansive market research database

U.S. Ketamine Clinics Market Size is Predicted to Witness 10.60% CAGR till 2030

The U.S. Ketamine Clinics Market size is anticipated to reach USD 6.90 billion by 2030, exhibiting a CAGR of 10.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market's growth can be attributed to the increase in mental health awareness, the ongoing opioid crisis, and an increasing number of ketamine clinics across the U.S. According to SAMHSA, in 2022, about 19.86% of adults, which is nearly 50 million people, had some form of mental illness, with 4.91% experiencing severe mental health conditions. The prevalence of mental illness varied by state, ranging from 16.37% in New Jersey to 26.86% in Utah.

Moreover, the COVID-19 pandemic had a negative impact on the mental health of adults, leading to an increased demand for innovative treatments. A survey by the Kaiser Family Foundation found that 39.3% of adults in the U.S. reported symptoms of anxiety or depressive disorder in February 2021, a significant increase from pre-pandemic levels. This increase in mental health issues has created the need for effective and rapid treatments, further driving the growth of the market in the U.S.

Moreover, the growing consolidation of local service providers with major ketamine clinic providers to offer ketamine treatments in the U.S. is expected to increase opportunities in the market. Market players are undertaking various strategic initiatives to increase their capabilities, improve competencies, and expand their service portfolios. For instance, in October 2023, Nue Life Health was acquired by a venture studio specializing in psychedelic healthcare. This acquisition aligned with the studio’s mission to advance innovative treatments in the mental wellness space, particularly through the use of psychedelic therapies.

List of Key Players in U.S. Ketamine Clinics Market

Better U, Inc.
Innerwell (KBS, Inc.)
Ketamine Clinics Los Angeles
Klarisana Health
Klarity Clinic (Tebra Inc.)
Mindbloom, Inc.
Nue Life Health (NueCo Holdings, P.B.C.)
NY Ketamine Infusions
Stella MSO LLC dba Field Trip Health
Vitalitas Denver Ketamine Infusion Center

Request a free sample copy or view report summary: U.S. Ketamine Clinics Market Report

U.S. Ketamine Clinics Market Report Highlights

Based on treatment, the depression segment held the largest market share in 2023. This can be attributed to the growing number of American adults burdened with severe major depression.
Based on therapy, the on-site therapy segment dominated the market with the largest market share in 2023 owing to the growing acceptance of ketamine therapy for mental health disorders which has led to an expansion of clinics in the U.S.
In February 2024, Avesta Ketamine and Wellness entered into a partnership with Veteran Affairs (VA) to provide free ketamine therapy to veterans across Maryland, Bethesda, Northern Virginia, and Washington DC. This initiative was expected to help veterans with substance abuse disorder, chronic pain, anxiety, PTSD, and treatment-resistant depression.

U.S. Ketamine Clinics Market Report Scope

Report Attribute	Details
Revenue forecast in 2030	USD 6.90 billion
Growth rate	CAGR of 10.60% from 2024 to 2030
Actual data	2018 - 2023
Forecast data	2024 - 2030

Related Press Release@ U.S. Ketamine Clinics Industry Analysis

U.S. Ketamine Clinics Market Segmentation

Grand View Research has segmented the U.S. ketamine clinics market based on treatment, and therapy:

U.S. Ketamine Clinics Treatment Outlook (Revenue, USD Million, 2018 - 2030)

Depression
Anxiety
PTSD
Others

U.S. Ketamine Clinics Therapy Outlook (Revenue, USD Million, 2018 - 2030)

On-site Therapy
Online Therapy

Explore Horizon, the world's most expansive market research database

Friday, 20 September 2024

Veterinary Imaging Market Size, Share, Growth | Industry Report, 2030

Veterinary Imaging Market Report Scope

Thursday, 19 September 2024

Plasma Protease C1-inhibitor Market To Reach $6.21 Billion By 2030

Plasma Protease C1-inhibitor Market Report Scope

South Korea Botulinum Toxin Type A Market Size is Predicted to Witness 10.4% CAGR till 2030

South Korea Botulinum Toxin Type A Market Report Scope

U.S. Ketamine Clinics Market Size is Predicted to Witness 10.60% CAGR till 2030

U.S. Ketamine Clinics Market Report Scope

Wound Gel Market Size To Reach $9.68 billion By 2033